MCID: CHR048
MIFTS: 54

Chronic Rhinitis

Categories: Bone diseases, Respiratory diseases, Smell/Taste diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Chronic Rhinitis

MalaCards integrated aliases for Chronic Rhinitis:

Name: Chronic Rhinitis 11 53 14 71 31 33
Chronic Rhinitis Nos 33
Rhinitis - Chronic 11
Rhinitis Nos 33
Rhinitis 33

Classifications:



External Ids:

Disease Ontology 11 DOID:8252
ICD9CM 34 472.0
NCIt 49 C34479
SNOMED-CT 68 155522005
ICD10 31 J31.0
ICD11 33 1346915097
UMLS 71 C0008711

Summaries for Chronic Rhinitis

Disease Ontology: 11 A rhinitis which is persistent and long-lasting. It may occur with diseases such as syphilis, tuberculosis, rhinoscleroma, rhinosporidiosis, leishmaniasis, blastomycosis, histoplasmosis, and leprosy, all of which are characterized by the formation of inflamed lesions (granulomas) and the destruction of soft tissue, cartilage, and bone. Chronic rhinitis causes nasal obstruction, pus-filled discharge from the nose, and frequent bleeding.

MalaCards based summary: Chronic Rhinitis, also known as chronic rhinitis nos, is related to giant papillary conjunctivitis and allergic conjunctivitis, and has symptoms including rhinorrhea, purulent rhinitis and catarrh. An important gene associated with Chronic Rhinitis is HRH1 (Histamine Receptor H1), and among its related pathways/superpathways are Hematopoietic Stem Cells and Lineage-specific Markers and Allograft rejection. The drugs Dexlansoprazole and Lansoprazole have been mentioned in the context of this disorder. Affiliated tissues include eye, skin and bone, and related phenotypes are immune system and respiratory system

Related Diseases for Chronic Rhinitis

Diseases in the Rhinitis family:

Chronic Rhinitis

Diseases related to Chronic Rhinitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 720)
# Related Disease Score Top Affiliating Genes
1 giant papillary conjunctivitis 31.5 RNASE3 IL5 IL4 IL13
2 allergic conjunctivitis 31.4 RNASE3 IL5 IL4 IL33 IL13 HRH1
3 rhinitis 31.3 RNASE3 IL5 IL4 IL33 IL13 HRH1
4 chronic urticaria 30.9 RNASE3 IL5 HRH1
5 allergic rhinitis 30.8 TAC1 RNASE3 IL5 IL4 IL13 HRH1
6 urticaria 30.7 TAC1 RNASE3 IL5 IL4 IL33 IL13
7 ige responsiveness, atopic 30.6 RNASE3 IL5 IL4 IL13
8 exercise-induced bronchoconstriction 30.6 RNASE3 IL5 IL4 IL13
9 hypereosinophilic syndrome 30.5 RNASE3 IL5 IL4 IL13
10 chronic spontaneous urticaria 30.5 IL5 IL4 IL33 IL13 HRH1
11 respiratory syncytial virus infectious disease 30.5 IL5 IL13
12 adenoid hypertrophy 30.3 IL5 IL4
13 vasomotor rhinitis 30.3 TAC1 RNASE3 IL5 IL4 IL13 HRH1
14 ascaris lumbricoides infection 30.2 IL5 IL4 IL13
15 acute asthma 30.2 RNASE3 IL5 IL4 IL33 IL13
16 occupational asthma 30.2 RNASE3 PEDS1 IL5 IL4 IL33 IL13
17 dermatitis, atopic 30.2 TAC1 RNASE3 PTGDR2 PEDS1 IL5 IL4
18 common cold 30.2 RNASE3 PTGDR2 IL5 IL4 IL33 IL13
19 allergic contact dermatitis 30.2 RNASE3 IL5 IL4 IL33 IL13
20 proteasome-associated autoinflammatory syndrome 1 30.1 RNASE3 IL5 IL4 IL13
21 eosinophilic gastroenteritis 30.1 RNASE3 IL5 IL4 IL13
22 fungal infectious disease 30.1 IL5 IL4 IL13
23 intrinsic asthma 30.1 RNASE3 IL5 IL4 IL33 IL13
24 diphtheria 30.0 IL5 IL4 IL13
25 meningitis 30.0 IL5 IL4 IL13
26 eosinophilic pneumonia 30.0 RNASE3 IL5 IL4 IL13
27 leishmaniasis 30.0 IL5 IL4 IL13
28 keratoconjunctivitis 30.0 RNASE3 IL5 IL4 IL13
29 bronchitis 30.0 TAC1 RNASE3 IL5 IL4 IL13
30 leprosy 3 30.0 IL5 IL4 IL13
31 blepharoconjunctivitis 30.0 IL4 IL13
32 ciliary dyskinesia, primary, 1 30.0 DNAH5 DNAH11 CCDC40
33 bronchiolitis 30.0 RNASE3 IL5 IL4 IL33 IL13
34 neurodermatitis 29.9 TAC1 IL4 IL13
35 parasitic helminthiasis infectious disease 29.9 RNASE3 IL5 IL4 IL33 IL13
36 enterobiasis 29.9 IL5 IL4
37 granulomatosis with polyangiitis 29.9 RNASE3 IL5 IL13
38 allergic asthma 29.9 RNASE3 IL5 IL4 IL13
39 otitis media 29.9 RNASE3 IL5 IL4 IL13
40 cough variant asthma 29.9 TAC1 RNASE3 IL5 IL4 IL13
41 esophagitis 29.8 RNASE3 IL5 IL4 IL33 IL13
42 gastroenteritis 29.8 RNASE3 IL5 IL4
43 tetanus 29.8 IL5 IL4 IL13
44 vernal keratoconjunctivitis 29.8 RNASE3 IL4 IL13
45 metal allergy 29.8 IL5 IL4 IL13
46 bronchiectasis 29.8 DNAH5 DNAH11 CCDC40
47 igg4-related disease 29.8 IL5 IL4 IL13
48 skin disease 29.8 TAC1 RNASE3 IL5 IL4 IL33 IL13
49 physical urticaria 29.7 TAC1 IL5 HRH1
50 bullous pemphigoid 29.7 RNASE3 IL5 IL4

Comorbidity relations with Chronic Rhinitis via Phenotypic Disease Network (PDN):


Anxiety Bronchitis
Esophagitis Heart Disease
Hypertension, Essential

Graphical network of the top 20 diseases related to Chronic Rhinitis:



Diseases related to Chronic Rhinitis

Symptoms & Phenotypes for Chronic Rhinitis

UMLS symptoms related to Chronic Rhinitis:


rhinorrhea; purulent rhinitis; catarrh

MGI Mouse Phenotypes related to Chronic Rhinitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.9 CCDC40 CCNO DNAH11 DNAH5 HRH1 IL13
2 respiratory system MP:0005388 9.61 CCDC40 CCNO DNAH11 DNAH5 IL13 IL33
3 hematopoietic system MP:0005397 9.4 CCDC40 CCNO DNAH11 DNAH5 HRH1 IL13

Drugs & Therapeutics for Chronic Rhinitis

Drugs for Chronic Rhinitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 273)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6 9578005
2
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
3
Loratadine Approved, Investigational Phase 4 79794-75-5 3957
4
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
5
Cetirizine Approved Phase 4 83881-51-0 2678
6
Fexofenadine Approved, Investigational Phase 4 83799-24-0 3348
7
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
8
Xylometazoline Approved, Investigational Phase 4 526-36-3 5709
9
Omalizumab Approved, Investigational Phase 4 242138-07-4
10
Terfenadine Approved, Withdrawn Phase 4 50679-08-8 5405
11
Salbutamol Approved, Vet_approved Phase 4 18559-94-9 2083
12
Ethanol Approved Phase 4 64-17-5 702
13
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
14
Prazosin Approved Phase 4 19216-56-9 4893
15
Doxazosin Approved Phase 4 74191-85-8 3157
16
Calcium carbonate Approved, Investigational Phase 4 471-34-1
17
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
18
Adenosine Approved, Investigational Phase 4 58-61-7 60961
19
Theophylline Approved Phase 4 58-55-9 2153
20
Mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7 4240 441336
21
Budesonide Approved Phase 4 51333-22-3 5281004 40000 63006
22
Wormwood Approved, Experimental Phase 4
23
Emedastine Approved Phase 4 87233-61-2 3219
24
Bepotastine Approved Phase 4 190786-44-8, 125602-71-3 2350 164522
25
Montelukast Approved Phase 4 158966-92-8 5281040
26
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
27
Resveratrol Investigational Phase 4 501-36-0 445154
28
Tranilast Investigational Phase 4 53902-12-8 5282230
29 Purple Butterbur Phase 4
30 Proton Pump Inhibitors Phase 4
31 Cholinergic Antagonists Phase 4
32 Cholinergic Agents Phase 4
33
Ethylene Phase 4 74-85-1 6325
34
Salmeterol Xinafoate Phase 4 94749-08-3
35 Epinephryl borate Phase 4
36
Beclomethasone Phase 4 2308 20469
37 Phosphodiesterase Inhibitors Phase 4
38 Interleukin-12 Phase 4
39 Mitogens Phase 4
40 Adrenergic beta-Agonists Phase 4
41 Platelet Aggregation Inhibitors Phase 4
42 Acidophilus Phase 4
43 Fluticasone-Salmeterol Drug Combination Phase 4
44 Lubricant Eye Drops Phase 4
45 Calcium, Dietary Phase 4
46 Tocolytic Agents Phase 4
47 Adrenergic Antagonists Phase 4
48 Adrenergic alpha-Antagonists Phase 4
49 Adrenergic alpha-1 Receptor Antagonists Phase 4
50 Antihypertensive Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 1130)
# Name Status NCT ID Phase Drugs
1 Real Life Proof-of-Concept Study to Assess the Effect of Methylcellulose as add-on "Seal" to the In-season Pharmacologic Rescue Treatment in Subjects With Allergic Rhinitis Unknown status NCT02557269 Phase 4 Xylometazoline - intranasal application;Azelastine - intranasal application;Mometasone furoate - intranasal application;Hydroxyl-propyl-methyl cellulose powder - intranasal application;Bilastine 20 mg;Prednisolone 5 mg
2 Comparison of the Effect of Montelukast and Cetirizine on Allergic Inflammation Measured by Exhaled Nitric Oxide Concentration in Children With Seasonal Allergic Rhinitis Unknown status NCT00488176 Phase 4 montelukast;cetirizine;montelukast and cetirizine;placebo
3 A Randomized, Parallel, Double-blind, Multi-center, Comparative Study to Exploratively Evaluate the Efficacy and Safety of Cosalin® Monotherapy vs. Cosalin® and Xarlin® Combination Therapy in Patients With Allergic Rhinitis Unknown status NCT01062139 Phase 4 Xarlin (Levocetirizine);Cosalin (Petasites hybridus CO2 extract)
4 Evaluating Factors Involved in Dymista's Superior Clinical Efficacy to Fluticasone Propionate in the Treatment of Seasonal Allergic Rhinitis Unknown status NCT02402465 Phase 4 Placebo;Fluticasone propionate;Fluticasone/Azelastine nasal spray
5 Randomized Controlled Trial Evaluating Combination Rupatadine and Fluticasone Propionate Compared to Azelastine Hydrochloride and Fluticasone Propionate in Treating Allergic Rhinitis Unknown status NCT04601324 Phase 4 Fluticasone Propionate;Azelastine hydrochloride and fluticasone propionate;Rupatadine
6 SINOL + MucoAd™ (SMAN) Evaluation Trial: A Double-Blind, Cross-Over Comparison of SINOL and SMAN in Subjects With Congestion Due to Allergic Rhinitis Unknown status NCT00825656 Phase 4 Sinol or Sinol-M nasal spray
7 Assessment of Effectiveness and Safety of Annual Sublingual Immunotherapy in Children With Bronchial Asthma and/or Allergic Rhinitis Allergic to House Dust Mites Unknown status NCT01052610 Phase 4 sublingual house dust mites allergen extract;placebo in sublingual applicator
8 AZE/FLU Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness in Allergic Rhinitis (AR) Unknown status NCT02238353 Phase 4 azelastine + fluticasone;Placebo
9 The Evaluation of Singulair for the Treatment of Non-Allergic Rhinitis Eosinophil Syndrome (NARES) Unknown status NCT00406094 Phase 4 montelukast;placebo
10 The Relationship Between Gastroesophageal Reflux and Pediatric Rhinitis: Significance of Pale/Blue Colored Turbinate. A Randomized Controlled Trial Unknown status NCT02278081 Phase 4 lansoprazole;placebo
11 Changes in Exhaled Breath Temperature During the Pollen Season in Subjects With Allergic Rhinoconjunctivitis Sensitized to Grasses and Effect of Sublingual Immunotherapy Unknown status NCT01785394 Phase 4 5 grass allergen extract
12 The Efficacy and Safety of Hyeonggaeyeongyo-tang for Chronic Rhinitis According to Pattern Identification in Korean Medicine Completed NCT02477293 Phase 4 Hyeonggaeyeongyo-tang
13 Preference Evaluation of Clarinex Tablets vs. Zyrtec Tablets in Subjects With Symptomatic Allergic Rhinitis Completed NCT00794599 Phase 4 Desloratadine 5 mg (Clarinex);Cetirizine (Zyrtec)
14 Preference Evaluation of Clarinex Tablets vs. Zyrtec Tablets in Subjects With Symptomatic Allergic Rhinitis Completed NCT00794846 Phase 4 Desloratadine 5 mg (Clarinex);Cetirizine (Zyrtec)
15 Study 200165, A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Compare the Efficacy of a 2-Week Treatment With Fluticasone Propionate Nasal Spray Versus Cetirizine in Adult Subjects With Seasonal Allergic Rhinitis (SAR) Completed NCT01916226 Phase 4 FPNS;FPNS Placebo;Cetirizine;Cetirizine Placebo
16 Preference Evaluation of Clarinex Tablets vs. Zyrtec Tablets in Subjects With Symptomatic Allergic Rhinitis Completed NCT00794495 Phase 4 Desloratadine 5 mg (Clarinex);Cetirizine (Zyrtec)
17 Single-Center, Double-Blind, Randomized , Parallel Study Comparing Onset of Action, Efficacy & Safety of a Single-Dose of Fexofenadine HCl 180 mg vs Montelukast Na 10 mg & Placebo in Treating Seasonal Allergic Rhinitis Subjects in an Allergen Exposure Unit (Study I) Completed NCT00637611 Phase 4 Fexofenadine HCl
18 A Phase IV, Open-label, Safety and Tolerability Trial of MK-3641 and MK-7243 Coadministered in Subjects At Least 18 Years of Age With Ragweed and Grass Pollen Induced Allergic Rhinitis With or Without Conjunctivitis Completed NCT02256553 Phase 4 Rescue Medication
19 A Multi-center, Open-label, Non-comparative Study of the Relief of Nasal Symptoms and Tolerability in Subjects With Seasonal Allergic Rhinitis (SAR) Treated With Aerius. Completed NCT00805584 Phase 4 desloratadine
20 A Monitored Release Study On The Efficacy And Safety of Fexofenadine (Telfast®) 30mg Pediatric Tablets On Filipino Children Aged 6 To 11 for The Relief of Perennial And Intermittent Allergic Rhinitis. Completed NCT00741897 Phase 4 Fexofenadine
21 Immunological Mechanisms of Oralair® (5 Grass Mix Sublingual Allergen Immunotherapy Tablet) in Patients With Seasonal Allergic Rhinitis Completed NCT02014623 Phase 4 Control
22 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Long-Term Treatment With Rhinocort Aqua (Budesonide) Nasal Spray in Children With Perennial Allergic Rhinitis. Completed NCT00641212 Phase 4 Budesonide;Placebo
23 Single Center, Randomized,Double-Blind,Crossover Study Comparing the Effects of Single-Dose Fexofenadine HCl 180 mg, Cetirizine 10 mg, and Placebo on Cognitive Performance in Naval Flight Personnel Completed NCT00637455 Phase 4 fexofenadine HCl
24 Randomized, Double-blind, Placebo-controlled Study to Measure 2L®ALERG (Homeopathic Drug) Efficacy on Symptoms of Allergic Rhinitis and Allergic Rhinoconjunctivitis in Patients With a Seasonal Allergy to Grass Pollen Completed NCT02690935 Phase 4 2LALERG;Placebo
25 Safety of PATANASE® Nasal Spray in Patients With Perennial Allergic Rhinitis Completed NCT00789555 Phase 4 Olopatadine hydrochloride 0.6% nasal spray (PATANASE)
26 A Placebo Controlled Study of the Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. in the Treatment of Subjects With Symptomatic Seasonal Allergic Rhinitis (SAR) Completed NCT00783146 Phase 4 desloratadine;fexofenadine;placebo
27 Clinical Trial to Assess Onset of Action of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray Delivered in a Single Spray (MP-AzeFlu) in the Treatment of Allergen-Induced Allergic Rhinitis Symptoms in Comparison to Placebo and Free Combination of Fluticasone Propionate Nasal Spray and Oral Loratadine Completed NCT03004131 Phase 4 Azelastine hydrochloride + fluticasone propionate nasal spray;Placebos;fluticasone propionate nasal spray + loratadine
28 Efficacy and Safety of Lectranal® in Treatment of Seasonal Allergic Rhinitis Symptoms Completed NCT00460538 Phase 4
29 A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine 5 mg Once Daily Given for 2 Weeks in Subjects 18 yr of Age and Older With Seasonal Allergic Rhinitis Completed NCT00653224 Phase 4 levocetirizine dihydrochloride;placebo
30 Preference Evaluation of Clarinex Tablets vs. Allegra Tablets in Subjects With Symptomatic Seasonal Allergic Rhinitis Completed NCT00794248 Phase 4 desloratadine 5 mg;fexofenadine
31 A Placebo Controlled Study of the Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. in the Treatment of Subjects With Symptomatic Seasonal Allergic Rhinitis (SAR) Completed NCT00783211 Phase 4 desloratadine;fexofenadine;placebo
32 Evaluation of Efficacy, Using the Number of Comfortable Days and the Safety of Levocetirizine Dihydrochloride, Administered Once Daily in the Evening for 30 Days, to Subjects Suffering From Perennial Allergic Rhinitis to House Dust Mites Completed NCT00521131 Phase 4 Levocetirizine dihydrochloride
33 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Two-Year Study to Evaluate the Ocular Safety of Once-Daily, Fluticasone Furoate Nasal Spray 110mcg in Adults and Adolescents 12 Years of Age and Older With Perennial Allergic Rhinitis Completed NCT00682643 Phase 4 fluticasone furoate nasal spray;vehicle placebo nasal spray
34 A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study to Assess the Dose-response Curve of Intranasal Fluticasone Propionate (25, 50, 100 and 200 μg, Once Daily for 8 Days) in the Vienna Challenge Chamber for the Purpose of Investigating the Sensitivity Completed NCT00848965 Phase 4 Fluticasone propionate;Placebo
35 Preference Evaluation of Clarinex Tablets vs. Allegra Tablets in Subjects With Symptomatic Seasonal Allergic Rhinitis Completed NCT00794768 Phase 4 desloratadine 5 mg;fexofenadine
36 Preference Evaluation of Clarinex Tablets vs. Allegra Tablets in Subjects With Symptomatic Seasonal Allergic Rhinitis Completed NCT00783133 Phase 4 Desloratadine 5 mg;fexofenadine
37 Montelukast as a Controller of Atopic Syndrome Completed NCT00559546 Phase 4 montelukast
38 Intranasal Steroids Prevent Antigen-Induced Hyperresponsiveness of the Nasal Ocular Response Completed NCT00473915 Phase 4 fluticasone furoate
39 A Comparison of Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis Completed NCT00435461 Phase 4 Fluticasone furoate and fexofenadine
40 Clinical Trial to Assess Onset of Action of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray Delivered in a Single Spray (Dymista) in the Treatment of Allergen-Induced Allergic Rhinitis Symptoms in Comparison to Placebo in an Environmental Exposure Unit (EEU) Completed NCT04652245 Phase 4 Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 3;Treatment B (Placebo): Nasal spray with no active dose (Dymista vehicle) at Visit 5;Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 5;Treatment B (Placebo): Nasal spray with no active dose (Dymista vehicle) at Visit 3
41 Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid Completed NCT00845195 Phase 4 Olopatadine HCl Nasal Spray, 0.6%;Azelastine HCl Nasal Spray, 0.1%
42 Quantitative-Qualitative Clinical Trial to Evaluate the Effectiveness of Individualized Homeopathic Treatment in Perennial Allergic Rhinitis Completed NCT00822406 Phase 4 homeopathic medicine;placebo
43 Protocol for Post-approval Commitment Study of Loratadine for PPK Analysis in Japanese Pediatric and Adults Patients Completed NCT00730912 Phase 4 loratadine
44 A Randomized, Double-blind, Placebo-controlled, Active Comparator, One-Week, Cross-Over, Multicenter Study to Evaluate the Efficacy and Patient Preference of Nasal Spray Characteristics of Once-Daily, Intranasal Administration of 110mcg Fluticasone Furoate Nasal Spray and 200mcg Fluticasone Propionate Nasal Spray in Adult Subjects With Seasonal Allergic Rhinitis Completed NCT00539006 Phase 4 FPNS;FFNS;placebo FPNS;placebo FFNS
45 A Randomized, Double-blind, Placebo-controlled, Active Comparator, One-Week, Cross-Over, Multicenter Study to Evaluate the Efficacy and Patient Preference of Nasal Spray Characteristics of Once-Daily, Intranasal Administration of 110mcg Fluticasone Furoate Nasal Spray and 200mcg Fluticasone Propionate Nasal Spray in Adult Subjects With Seasonal Allergic Rhinitis Completed NCT00519636 Phase 4 FPNS;FFNS;placebo FFNS;placebo FPNS
46 A Comparison of Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis Completed NCT00502775 Phase 4 fluticasone furoate, fexofenadine
47 A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel Group Study of the 12 Month Effect of Treatment With Once Daily Triamcinolone Acetonide (NASACORT® AQ Nasal Spray 110 μg) on the Growth Velocity of Children, 3 to 9 Years of Age, With Perennial Allergic Rhinitis (PAR) Completed NCT00449072 Phase 4 TAA-AQ, Nasacort® AQ;Claritin®
48 Allergic Rhinitis Changes the Sinus Microbiome Completed NCT01852513 Phase 4 QNASL;Placebo nasal spray
49 A Double-masked, Randomized, Parallel Group, Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial Completed NCT00691665 Phase 4 Olopatadine HCL Nasal Spray, 0.6%;Fluticasone Propionate Nasal Spray, 50 mcg
50 A Multi-Centre, Double-Blind, Randomised Comparison Of The Effects Of Desloratadine (Aerius®) And Placebo In The Relief Of Nasal Symptom Scores In Subjects With Seasonal Allergic Rhinitis (Sar) To Cypress Pollen Completed NCT00867191 Phase 4 Placebo;Desloratadine

Search NIH Clinical Center for Chronic Rhinitis

Genetic Tests for Chronic Rhinitis

Anatomical Context for Chronic Rhinitis

Organs/tissues related to Chronic Rhinitis:

MalaCards : Eye, Skin, Bone, T Cells, Pituitary, Lung, Whole Blood

Publications for Chronic Rhinitis

Articles related to Chronic Rhinitis:

(show top 50) (show all 29900)
# Title Authors PMID Year
1
Further improvement of quality of life by cetirizine in perennial allergic rhinitis as a function of treatment duration. 53 62
10879992 2000
2
Allergic rhinitis in children: effects of flunisolide and disodium cromoglycate on nasal eosinophil cationic protein. 53 62
9088653 1997
3
Upper Airway Cough Syndrome. 62
36283869 2023
4
Unified Airway Disease: Future Directions. 62
36410990 2023
5
Monoclonal Antibodies (Biologics) for Allergic Rhinitis, Asthma, and Atopic Dermatitis During Pregnancy and Lactation. 62
36411004 2023
6
Unified Airway Disease: Genetics and Epigenetics. 62
36410991 2023
7
Unified Airway Disease: Examining Prevalence and Treatment of Upper Airway Eosinophilic Disease with Comorbid Asthma. 62
36266106 2023
8
Unified Airway Disease: A Contemporary Review and Introduction. 62
36266105 2023
9
Non-Eosinophilic Granulomatous Disease and the Unified Airway. 62
36410993 2023
10
Management of the Upper Airway Distress During Pregnancy. 62
36411008 2023
11
Longitudinal Changes in Upper and Lower Airway Function in Pregnancy. 62
36411003 2023
12
A well-characterized polycistronic-like gene expression system in yeast. 62
36168285 2023
13
Systematic Review of Surgical Interventions for Inferior Turbinate Hypertrophy. 62
36315624 2023
14
The Objective Assessment of dry Nose. 62
36330650 2023
15
Early-life exposure to air pollution associated with food allergy in children: Implications for 'one allergy' concept. 62
36347392 2023
16
Early life exposure to outdoor air pollution and indoor environmental factors on the development of childhood allergy from early symptoms to diseases. 62
36252839 2023
17
ESP-B4 promotes nasal epithelial cell-derived extracellular vesicles containing miR-146a-5p to modulate Smad3/GATA-3 thus relieving allergic rhinitis: ESP-B4/miR-146a-5p in AR. 62
36370637 2023
18
Effects of Combined Visible and Infrared Light Rhinophototherapy in Patients With Allergic Rhinitis. 62
36266929 2023
19
Zinc supplement reduces allergic responses through modulating the p38 MAPK pathway activation in an allergic rhinitis mouse model. 62
36265320 2023
20
Daphnetin Mitigates Ovalbumin-Induced Allergic Rhinitis in Mice by Regulating Nrf2/HO-1 and TLR4/NF-kB Signaling. 62
36128844 2023
21
The effect of the COVID-19 pandemic lockdown on symptom severity in school children with house dust mite-sensitized allergic rhinitis. 62
35875051 2022
22
Is Posterior Nasal Nerve Ablation Effective in Treating Symptoms of Allergic Rhinitis? 62
35938876 2022
23
Association of individual green space exposure with the incidence of asthma and allergic rhinitis: a systematic review and meta-analysis. 62
36329245 2022
24
A Pilot Study of Transdermal Application of Diphenhydramine to the Nasal Ala in Patients with Allergic Rhinitis and Asthma. 62
36420548 2022
25
Clinical efficacy of synbiotics in children with allergic rhinitis: An observational cohort study from a private medical center in Peru. 62
36444623 2022
26
Efficacy and safety of acupoint application for allergic rhinitis: a systematic review and Meta-analysis of randomized controlled trials. 62
36378042 2022
27
Bilirubin level is decreased in patients with allergic rhinitis. 62
36470582 2022
28
Water-extracted Lonicera japonica polysaccharide attenuates allergic rhinitis by regulating NLRP3-IL-17 signaling axis. 62
36184153 2022
29
Shufeng Jiedu capsule ameliorates olfactory dysfunction via the AMPK/mTOR autophagy pathway in a mouse model of allergic rhinitis. 62
36116201 2022
30
Combined medical therapy in the treatment of allergic rhinitis: Systematic review and meta-analyses. 62
35446512 2022
31
Association of self-reported allergic rhinitis with dengue severity: A case-control study. 62
36063904 2022
32
25-year retrospective longitudinal study on seasonal allergic rhinitis associations with air temperature in general practice. 62
36473873 2022
33
Monitoring disease activity of pollen allergies: What crowdsourced data are telling us. 62
36438191 2022
34
Medical management of rhinitis in pregnancy. 62
35131140 2022
35
ILC3-like ILC2 subset increases in minimal persistent inflammation after acute type II inflammation of allergic rhinitis and inhibited by Biminkang: Plasticity of ILC2 in minimal persistent inflammation. 62
36161355 2022
36
Prediction of clinical efficacy of subcutaneous immunotherapy for Artemisia sieversiana pollen allergic rhinitis by serum metabolomics. 62
35623930 2022
37
Tanshinone IIA alleviates ovalbumin-induced allergic rhinitis symptoms by inhibiting Th2 cytokine production and mast cell histamine release in mice. 62
35167426 2022
38
Local nasal immunotherapy for allergic rhinitis: A systematic review and meta-analysis. 62
35543418 2022
39
Trajectories of cough without a cold in early childhood and associations with atopic diseases. 62
36453463 2022
40
Inter-individual characteristics on basic taste recognition thresholds in a college-aged cohort: potential predictive factors. 62
36454091 2022
41
Adults with concomitant atopic dermatitis and asthma have more frequent urgent healthcare utilization and less frequent scheduled follow-up visits than adults with atopic dermatitis or asthma only: a nationwide cohort study. 62
35796157 2022
42
Polygenic risk score for ACE-inhibitor-associated cough based on the discovery of new genetic loci. 62
35751511 2022
43
Asthma, allergic rhinitis and atopic dermatitis in association with home environment - The RHINE study. 62
36089044 2022
44
Exome variants associated with asthma and allergy. 62
36470944 2022
45
The role of dendritic cells in allergic diseases. 62
36403519 2022
46
Exploring the Heterogeneity of IgE-Mediated Food Allergy through Latent Class Analysis. 62
36470226 2022
47
Childhood blood eosinophils and symptoms of allergic disorders: a cross-sectional study in Southern China. 62
36259652 2022
48
A green spectrophotometric method for the simultaneous determination of nasal binary mixture used in respiratory diseases: Applying isosbestic point and chemometric approaches as a resolving tool, greenness evaluation. 62
35988471 2022
49
Greenspace and health outcomes in children and adolescents: A systematic review. 62
36122655 2022
50
Asthma and pregnancy in the 2020 decade: still a matter of concern. 62
33926358 2022

Variations for Chronic Rhinitis

Expression for Chronic Rhinitis

Search GEO for disease gene expression data for Chronic Rhinitis.

Pathways for Chronic Rhinitis

GO Terms for Chronic Rhinitis

Cellular components related to Chronic Rhinitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 9+0 motile cilium GO:0097728 8.92 DNAH5 DNAH11

Biological processes related to Chronic Rhinitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cilium movement GO:0003341 9.85 DNAH5 DNAH11 CCDC40
2 positive regulation of B cell proliferation GO:0030890 9.8 IL13 IL4 IL5
3 positive regulation of mast cell degranulation GO:0043306 9.76 IL4 IL13
4 type 2 immune response GO:0042092 9.73 IL4 IL33
5 regulation of cilium beat frequency GO:0003356 9.71 DNAH11 CCDC40
6 multi-ciliated epithelial cell differentiation GO:1903251 9.56 MCIDAS CCNO
7 negative regulation of complement-dependent cytotoxicity GO:1903660 9.46 IL4 IL13
8 positive regulation of immunoglobulin production GO:0002639 9.43 IL5 IL33 IL13
9 epithelial cilium movement involved in extracellular fluid movement GO:0003351 9.02 DNAH5 DNAH11 CCDC40

Molecular functions related to Chronic Rhinitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.23 IL5 IL4 IL33 IL13

Sources for Chronic Rhinitis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....